BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts ...
Atai Life Sciences announced positive results from Beckley Psytech's Phase 2a study of BPL-003, an adjunctive treatment for patients with treatment-resistant depression (TRD) who are already on ...
Continued pipeline progress, including positive Phase 2a results for EMP‑01 and expected Phase 2 topline for VLS-01 in H2 2026 Replay and presentation materials available on AtaiBeckley’s investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results